Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
In a recent study of people whose previous hep C regimen failed to cure their infection, Vosevi cured almost all of them.
Ninety-seven percent of those who took the Gilead regimen after failing a previous therapy were cured in a recent study.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.
The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
Having hepatitis C with evidence of resistance to medications did not impact the chances of a cure in a recent study.
One research team has broken down the risk and benefits associated with treating more people in eight weeks or fewer.
Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.
It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.
A promising new regimen that will address unmet needs for this population is poised for FDA approval.
A look at Vosevi, the newest treatment for chronic hepatitis C virus infection for people without cirrhosis or with compensated cirrhosis
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.